WO2001068112A3 - Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility - Google Patents

Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility Download PDF

Info

Publication number
WO2001068112A3
WO2001068112A3 PCT/EP2001/002882 EP0102882W WO0168112A3 WO 2001068112 A3 WO2001068112 A3 WO 2001068112A3 EP 0102882 W EP0102882 W EP 0102882W WO 0168112 A3 WO0168112 A3 WO 0168112A3
Authority
WO
WIPO (PCT)
Prior art keywords
antro
duodenal motility
pyloro
glucagon
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/002882
Other languages
French (fr)
Other versions
WO2001068112A2 (en
Inventor
Burkhard Goeke
Joerg Schirra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002402733A priority Critical patent/CA2402733A1/en
Priority to AU2001252201A priority patent/AU2001252201A1/en
Priority to MXPA02009031A priority patent/MXPA02009031A/en
Priority to EP01925452A priority patent/EP1267912A2/en
Priority to JP2001566676A priority patent/JP2003526671A/en
Publication of WO2001068112A2 publication Critical patent/WO2001068112A2/en
Publication of WO2001068112A3 publication Critical patent/WO2001068112A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.
PCT/EP2001/002882 2000-03-14 2001-03-14 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility Ceased WO2001068112A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002402733A CA2402733A1 (en) 2000-03-14 2001-03-14 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
AU2001252201A AU2001252201A1 (en) 2000-03-14 2001-03-14 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
MXPA02009031A MXPA02009031A (en) 2000-03-14 2001-03-14 Effects of glucagon like peptide 1 (7 36) on antro pyloro duodenal motility.
EP01925452A EP1267912A2 (en) 2000-03-14 2001-03-14 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
JP2001566676A JP2003526671A (en) 2000-03-14 2001-03-14 Effect of glucagon-like peptide-1 (7-36) on antrum-duodenal motility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18909100P 2000-03-14 2000-03-14
US60/189,091 2000-03-14

Publications (2)

Publication Number Publication Date
WO2001068112A2 WO2001068112A2 (en) 2001-09-20
WO2001068112A3 true WO2001068112A3 (en) 2002-03-07

Family

ID=22695893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002882 Ceased WO2001068112A2 (en) 2000-03-14 2001-03-14 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility

Country Status (9)

Country Link
US (2) US6579851B2 (en)
EP (1) EP1267912A2 (en)
JP (1) JP2003526671A (en)
KR (1) KR20030009389A (en)
CN (1) CN1487836A (en)
AU (1) AU2001252201A1 (en)
CA (1) CA2402733A1 (en)
MX (1) MXPA02009031A (en)
WO (1) WO2001068112A2 (en)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
DE60335608D1 (en) * 2002-02-27 2011-02-17 Pharmain Corp COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2006501820A (en) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン Modified GLP-1 receptor agonists and their pharmacological uses
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
DE10316583A1 (en) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination
EP1729580B1 (en) 2004-03-30 2018-04-11 Monsanto Technology LLC Methods for controlling plant pathogens using n-phosphonomethylglycine
WO2005099724A2 (en) * 2004-04-13 2005-10-27 Parallel Solutions, Inc. Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1811935B1 (en) 2004-09-28 2016-03-30 Atrium Medical Corporation Heat cured gel and method of making
US9000040B2 (en) * 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CN101193626A (en) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 Controlled release formulation of octreotide
US20090305964A1 (en) * 2005-04-21 2009-12-10 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CN101258163B (en) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1 pharmaceutical compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
KR101529318B1 (en) 2005-12-19 2015-06-16 파마인 코포레이션 A hydrophobic core carrier composition for delivering a therapeutic agent, a method for preparing the same, and a method for using the composition
KR101106510B1 (en) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 Two-piece, internal-channel osmotic delivery system flow modulator
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
BRPI0807350A2 (en) * 2007-02-05 2014-05-06 Univ Singapore PUTATIVE CHITOCINE RECEIVER AND METHODS FOR USE
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008134425A1 (en) * 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2729139C (en) 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
EP2303226B1 (en) * 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
WO2010090988A2 (en) * 2009-02-06 2010-08-12 The Procter & Gamble Company Collapsible water-containing capsules
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
CA2758200A1 (en) * 2009-04-10 2010-10-14 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
US10555527B2 (en) * 2009-05-18 2020-02-11 Monsanto Technology Llc Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en) * 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
RU2547990C2 (en) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Fast achievement and/or completion of substantial stable drug delivery
BR112012015653B1 (en) * 2009-12-29 2023-09-26 W.R. Grace & Co. -Conn. COMPOSITION COMPRISING A POROUS PARTICULATE SILICA MATERIAL AND TRANSPARENT FILM COMPRISING THE SAME
US10729625B2 (en) * 2010-02-04 2020-08-04 Isp Investments Llc Self adapting polymers for anhydrous sunscreen formulations
FR2958155B1 (en) * 2010-04-02 2012-04-20 Oreal DECOLORATION COMPOSITION COMPRISING PEROXYGEN SALT IN A HIGHLY RICH BODY BASE
WO2011137563A1 (en) 2010-05-07 2011-11-10 Unilever Plc High solvent content emulsions
NZ603506A (en) 2010-06-04 2013-11-29 Monsanto Technology Llc Transgenic brassica event mon 88302 and methods of use thereof
JP2013530993A (en) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド Short and D-amino acid containing polypeptides for therapeutic conjugates and uses thereof
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
CA2807171A1 (en) * 2010-08-19 2012-02-23 Pioneer Hi-Bred International, Inc. Novel bacillus thuringiensis gene with lepidopteran activity
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2836911A1 (en) * 2011-06-04 2012-12-13 Ian S. CURTIS Potato transformation compositions, systems, methods, microorganisms, and plants
US9826763B2 (en) * 2011-10-05 2017-11-28 Fmc Corporation Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
US9492363B1 (en) * 2012-01-16 2016-11-15 American Spraytech, L.L.C. Aerosol sprayable color composition
EP2806862A2 (en) * 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
CN104736177A (en) * 2012-08-03 2015-06-24 Msm创新有限公司 Method and kit for bowel preparation
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
AU2013302756C1 (en) 2012-08-14 2018-05-17 10X Genomics, Inc. Microcapsule compositions and methods
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
CA2894694C (en) 2012-12-14 2023-04-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
KR20200140929A (en) 2013-02-08 2020-12-16 10엑스 제노믹스, 인크. Polynucleotide barcode generation
US8961680B2 (en) * 2013-03-08 2015-02-24 Tbf Environmental Technology Inc. Solvent formulations
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc Bioerodible silicon-based compositions for delivery of therapeutic agents
WO2014152189A1 (en) * 2013-03-15 2014-09-25 Maria Beug-Deeb Inc. Dba T&M Associates Methods and compositions for cleaning and disinfecting surfaces
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
EP3421033B1 (en) * 2013-10-07 2022-07-27 Bristol-Myers Squibb Holdings Ireland Unlimited Company Hiv treatment formulation of atazanavir and cobicistat
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
BR112016023625A2 (en) 2014-04-10 2018-06-26 10X Genomics, Inc. fluidic devices, systems and methods for encapsulating and partitioning reagents, and applications thereof
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CA2953469A1 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Analysis of nucleic acid sequences
WO2015200893A2 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
JP6640826B2 (en) 2014-07-08 2020-02-05 ミメディクス グループ インコーポレイテッド Micronized Walton Colloid
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
HUE053962T2 (en) * 2014-09-11 2021-08-30 Gelita Ag Gelatin/pectin particles
US10646607B2 (en) * 2014-09-17 2020-05-12 Lonza, Inc. Activated disinfectant hydrogen peroxide compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
BR112017008877A2 (en) 2014-10-29 2018-07-03 10X Genomics Inc methods and compositions for targeting nucleic acid sequencing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
CN107106600A (en) * 2015-01-06 2017-08-29 山田修 Pharmaceutical compositions, blood treatment devices, cosmetics, and food and beverages utilizing combustion synthetic materials
JP6769969B2 (en) 2015-01-12 2020-10-14 １０エックス ジェノミクス， インコーポレイテッド Processes and systems for making nucleic acid sequencing libraries, and libraries made using them
MX2017010857A (en) 2015-02-24 2017-12-11 10X Genomics Inc Methods for targeted nucleic acid sequence coverage.
EP3262407B1 (en) 2015-02-24 2023-08-30 10X Genomics, Inc. Partition processing methods and systems
WO2016137804A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US20160303043A1 (en) * 2015-04-16 2016-10-20 Kate Somerville Skincare, LLC Self-foaming compositions and methods
RU2730996C2 (en) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Implant installation and extraction systems
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US20170009184A1 (en) 2015-07-10 2017-01-12 The Procter & Gamble Company Fabric care composition comprising metathesized unsaturated polyol esters
JP6954899B2 (en) 2015-12-04 2021-10-27 １０エックス ゲノミクス，インコーポレイテッド Methods and compositions for nucleic acid analysis
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
KR102574993B1 (en) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2017293856B2 (en) 2016-07-08 2020-04-02 The Gillette Company Llc Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters
DE102016223333A1 (en) * 2016-11-24 2018-05-24 Henkel Ag & Co. Kgaa Alkaline hair whitening agents containing oxidizing agents and specific carboxylic esters as keratin crosslinkers
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
JP7286542B2 (en) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド A method comprising continuous administration of a GLP-1 receptor agonist and co-administration of drugs
EP4029939B1 (en) 2017-01-30 2023-06-28 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
IL268997B2 (en) * 2017-03-01 2023-09-01 Arena Pharm Inc Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
EP3445876B1 (en) 2017-05-26 2023-07-05 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
US12151014B2 (en) * 2017-09-18 2024-11-26 Mast Industries (Far East) Limited Gloss lip balm formulation
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
CN112262218B (en) 2018-04-06 2024-11-08 10X基因组学有限公司 Systems and methods for quality control in single cell processing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039022A1 (en) * 1997-03-03 1998-09-11 1149336 Ontario Inc. Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous system
WO1999064060A1 (en) * 1998-06-11 1999-12-16 Hellstroem Per Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002506792A (en) * 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ N-terminal modified GLP-1 derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039022A1 (en) * 1997-03-03 1998-09-11 1149336 Ontario Inc. Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous system
WO1999064060A1 (en) * 1998-06-11 1999-12-16 Hellstroem Per Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ANVARI M ET AL: "Effect of GLP-1 on antropyloric motility, transpyloric flow and gastric emptying of non-nutrient liquids in conscious dogs.", GASTROENTEROLOGY, vol. 108, no. 4 SUPPL., 1995, 95th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week;San Diego, California, USA; May 14-17, 1995, pages A563, XP001012952, ISSN: 0016-5085 *
ANVARI M ET AL: "Sites of action of GLP-1 to inhibit transpyloric flow and gastric emptying of non-nutrient liquids in conscious dogs.", CLINICAL AND INVESTIGATIVE MEDICINE, vol. 18, no. 4 SUPPL., 1995, Annual Meeting of the Canadian Society for Clinical Investigation and the Royal College of Physicians and Surgeons of Canada;Montreal, Quebec, Canada; September 13-17, 1995, pages B56, XP001013012, ISSN: 0147-958X *
ANVARI MEHRAN ET AL: "Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid.", DIGESTIVE DISEASES AND SCIENCES, vol. 43, no. 6, June 1998 (1998-06-01), pages 1133 - 1140, XP001013009, ISSN: 0163-2116 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1979, QVIGSTAD T ET AL: "Comparison of Glucagon Atropine and Placebo as Pre Medication for Endoscopy of the Upper Gastro Intestinal Tract", XP002174496, Database accession no. PREV197968075464 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, CHANG F-Y ET AL: "A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography", XP002174497, Database accession no. PREV199598218113 *
GIRALT M ET AL: "Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat.", REGULATORY PEPTIDES, vol. 74, no. 1, 24 April 1998 (1998-04-24), pages 19 - 25, XP001013010, ISSN: 0167-0115 *
MOSE P L ET AL: "Suppression of duodenal motility during ERCP by L-hyoscyamine versus glucagon: A randomized, prospective, double blinded trial.", GASTROENTEROLOGY, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), Digestive Disease Week and the 99th Annual Meeting of the American Gastroenterological Association;New Orleans, Louisiana, USA; May 16-22, 1998, pages A533, XP001013004, ISSN: 0016-5085 *
NASLUND ERIK ET AL: "Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying.", DIGESTIVE DISEASES AND SCIENCES, vol. 43, no. 5, May 1998 (1998-05-01), pages 945 - 952, XP001013043, ISSN: 0163-2116 *
NAUCK M A: "Is glucagon - like peptide 1 an incretin hormone?.", DIABETOLOGIA, (1999 MAR) 42 (3) 373-9. REF: 67, XP001013315 *
QUIGLEY E.M.M.: "Gastroduodenal motility.", CURRENT OPINION IN GASTROENTEROLOGY, (1999) 15/6 (481-491)., XP001013511 *
SCHIRRA J ET AL: "Differential effects of subcutaneous GLP - 1 on gastric emptying, antroduodenal motility, and pancreatic function in men.", PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, (1997 JAN) 109 (1) 84-97., XP001013311 *
SCHIRRA J ET AL: "Differential effects of subcutaneous GLP-1 on gastric emptying, insulin release and exocrine pancreatic secretion in man.", GASTROENTEROLOGY, vol. 108, no. 4 SUPPL., 1995, 95th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week;San Diego, California, USA; May 14-17, 1995, pages A1003, XP001013040, ISSN: 0016-5085 *
SCHIRRA J ET AL: "Effects of GLP-1 on human antro-pyloro-duodenal motility.", GASTROENTEROLOGY, vol. 110, no. 4 SUPPL., 1996, 96th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week;San Francisco, California, USA; May 19-22, 1996, pages A1116, XP001012953, ISSN: 0016-5085 *
SCHIRRA J ET AL: "Effects of GLP-1 on pyloric motility and endocrine pancreatic response in the interdigestive state and with duodenal lipid.", GASTROENTEROLOGY, vol. 116, no. 4 PART 2, April 1999 (1999-04-01), Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association;Orlando, Florida, USA; May 16-19, 1999, pages A643, XP001008660, ISSN: 0016-5085 *
SCHIRRA J ET AL: "Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.", GUT, vol. 46, no. 5, May 2000 (2000-05-01), pages 622 - 631, XP001013031, ISSN: 0017-5749 *
SCHIRRA J ET AL: "Endogenous GLP-1(7-36)amide controls endocrine pancreatic secretion and antroduodenal motility in human.", GASTROENTEROLOGY, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), Digestive Diseases Week and the 99th Annual Meeting of the American Gastroenterological Association;New Orleans, Louisiana, USA; May 16-22, 1998, pages A1178, XP001013003, ISSN: 0016-5085 *
See also references of EP1267912A2 *
TOLESSA TESFAYE ET AL: "Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.", JOURNAL OF CLINICAL INVESTIGATION, vol. 102, no. 4, 15 August 1998 (1998-08-15), pages 764 - 774, XP001012974, ISSN: 0021-9738 *
VECHT J ET AL: "The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment.", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. SUPPLEMENT, (1997) 223 21-7. REF: 95, XP001013316 *

Also Published As

Publication number Publication date
MXPA02009031A (en) 2004-08-19
US20020098195A1 (en) 2002-07-25
JP2003526671A (en) 2003-09-09
KR20030009389A (en) 2003-01-29
WO2001068112A2 (en) 2001-09-20
US6579851B2 (en) 2003-06-17
US20030216292A1 (en) 2003-11-20
EP1267912A2 (en) 2003-01-02
CA2402733A1 (en) 2001-09-20
CN1487836A (en) 2004-04-07
AU2001252201A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
WO2003061362A3 (en) Methods and compositions for treating polycystic ovary syndrome
DK1412357T3 (en) Beta-aminotetrahydroimidazo (1,2-a) pyrazines and tetrahydrotriazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PL343104A1 (en) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
IL183953A0 (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical, or stored blood
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
WO2004060313A3 (en) Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
WO2003057144A3 (en) Change inhibitors of dipeptidyl peptidase iv
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
WO2003094617A3 (en) Use of vegf for treating bone defects
WO2002019918A3 (en) Fluorescent surgical device
WO2002041837A3 (en) Treatment of mucositis
WO2004007520A3 (en) Methods and compositions for preventing oxidative degradation of proteins
CA2262647A1 (en) Methods for regulating gastrointestinal motility
AU2002319961A1 (en) Enteral compositions for the prevention and/or treatment of sepsis
WO2006014618A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
MXPA03009772A (en) Methods and compositions for treating oral and eosophageal lesions.
HUP0300725A2 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
WO2006032091A3 (en) Herbal composition
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
WO2002053106A3 (en) Autoantigen composition
NO20011537L (en) Chemokine receptor peptide vaccines for the treatment and prevention of diabetes
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
WO2004091436A3 (en) Methods and compositions for treating ocular disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2402733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009031

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027012132

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00901/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 566676

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001252201

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001925452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018093507

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001925452

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027012132

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 2001925452

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001925452

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020027012132

Country of ref document: KR